ELIAS ZERHOUNI

Elias Zerhouni stands as a pivotal figure in both the scientific and investment communities, currently serving as a distinguished Venture Partner at Catalio Capital. His role at Catalio Capital leverages his profound understanding of biomedical science and healthcare innovation to identify and nurture groundbreaking technologies. Catalio Capital is renowned for its focus on breakthrough biomedical technologies, and Dr. Zerhouni's insights are instrumental in guiding investments in areas such as biotechnology, medical devices, diagnostics, and novel therapeutics.

Dr. Zerhouni's career background is marked by a series of high-impact leadership positions that have significantly shaped global health and scientific research. Prior to joining Catalio Capital, he held the prestigious role of Director of the National Institutes of Health (NIH) from 2002 to 2008. During his tenure at the NIH, he oversaw a vast portfolio of medical research, advocating for increased funding and spearheading initiatives that advanced our understanding and treatment of numerous diseases. His leadership at the NIH was characterized by a commitment to fostering innovation and translating scientific discoveries into tangible health benefits for the public.

Following his impactful period at the NIH, Dr. Zerhouni transitioned to the pharmaceutical industry, serving as President of Global Research and Development at Sanofi from 2011 to 2018. In this capacity, he was responsible for the company's worldwide R&D efforts, driving the development of new medicines and vaccines across various therapeutic areas. His strategic vision and scientific acumen were crucial in navigating the complexities of drug discovery and development, bringing vital treatments to patients globally. His work at Sanofi underscored his ability to bridge the gap between fundamental research and commercial application.

Beyond these executive roles, Elias Zerhouni is a highly respected physician-scientist and radiologist. His academic contributions and clinical expertise have earned him membership in both the National Academy of Medicine and the National Academy of Engineering, testaments to his multidisciplinary impact. While specific individual investments as a Venture Partner at Catalio Capital are proprietary, his influence is felt through the strategic direction and due diligence he provides, ensuring that Catalio invests in ventures with the highest potential for scientific and commercial success. His career trajectory demonstrates a consistent dedication to advancing medical science and improving human health, making him an invaluable asset to the life sciences investment landscape.